MedTrace Logo

Mechanical Diagnosis and Treatment and/or Steroid Injections for Lumbar Radiculopathy

NCT02951377 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-04-11

No results posted yet for this study

Summary

Aim 1: The primary aim of this study is to test the feasibility of Mechanical Diagnosis and Treatment (MDT) +/- transforaminal epidural steroid injections (TESI) on pain and disability in patients awaiting physiatry consult for lumbar radiculopathy secondary to lumbar disc herniation, compared to usual care within the current healthcare system in Calgary, Alberta, Canada.

Hypothesis: the investigators hypothesise that centralisers treated with MDT and non-centralisers receiving TESIs + MDT will have demonstrate reductions in self-reported pain and disability, compared to usual care controls.

Aim 2: the investigators will also describe the potential impact on healthcare resources by tracking surgical rates and self-reported healthcare utilisation during the study period.

Hypothesis: based on predicted reductions in pain and disability, the investigators hypothesise that there will be a trend toward overall less healthcare utilisation (including surgery) in the MDT guided group compared to the surgical wait list group.

Conditions

  • Sciatica
  • Lumbosacral Radiculopathy
  • Lumbar Disc Rupture

Interventions

OTHER

Exercise (MDT approach)

Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.

DRUG

Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)

An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Alberta College and Association of Phyiotherapists

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951377 on ClinicalTrials.gov